New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2013
07:32 EDTDNDNDendreon reports Q4 EPS (26c), consensus (56c)
Reports Q4 revenue $85.5M, consensus $82.88M. The company expects to reduce cost of goods sold to below 50% of net product revenue in the beginning of 3Q13. Expects to begin to see net benefits associated with the restructuring initiatives to begin to appear in financial results as early as 1H13, with full benefits realized in Q313. Says actively evaluating partnering strategies for European expansion; continuing to enroll patients in the sipuleucel-T European Union open-label study; expect a mid-2013 regulatory decision in Europe.
News For DNDN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 14, 2015
08:33 EDTDNDNDendreon says achieved cash-flow break even in Q4
Dendreon Corporation announced that the company grew sales in four quarters successively, exceeded its revenue target for the first time ever, and achieved cash-flow break even in Q4, starting 2015 on a strong footing. In addition, the first commercial European patient initiated treatment with PROVENGE in Germany the first country outside of the U.S. to offer the novel immunotherapy for advanced prostate cancer since receiving marketing authorization in the EU in 2013. Dendreon finished 2014 strong with a net product revenue for the year ended December 31, 2014 of $303.8M compared to $283.7M for the year ended December 31, 2013. Net product revenue for the fourth quarter ended December 31, 2014 was $79.8 million compared to $74.8 million for Q4. As of December 31, 2014, Dendreon had approximately $122M in cash, cash equivalents, and short-term and long-term investments. In early January, the first commercial patient in Germany began treatment with PROVENGE for advanced prostate cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use